A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

about

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

P2860

Q59128489-B74FA217-B52A-4103-99B3-2D07725B67EC

P2860

A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q38839151

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A Delphi consensus and open de ...... tive metastatic breast cancer.

@en

type

Item

label

A Delphi consensus and open de ...... tive metastatic breast cancer.

@en

prefLabel

A Delphi consensus and open de ...... tive metastatic breast cancer.

@en

P1476

A Delphi consensus and open de ...... tive metastatic breast cancer.

@en

P2093

Annamaria Molino

http://www.w3.org/2001/XMLSchema#string

Caterina Fontanella

http://www.w3.org/2001/XMLSchema#string

Giancarlo Bisagni

http://www.w3.org/2001/XMLSchema#string

Luigi Leo

http://www.w3.org/2001/XMLSchema#string

Mariangela Ciccarese

http://www.w3.org/2001/XMLSchema#string

Rosa Rita Silva

http://www.w3.org/2001/XMLSchema#string

Teresa Gamucci

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted Therapies in Triple-Negative Breast Cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

Ensuring equity of access to primary health care in rural and remote Australia - what core services should be locally available?

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

P304

2589-2602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0295

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fabio Puglisi

Paolo Marchetti

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27443691

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

about

P2860

P2860

A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921